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Abstract
Genetic variation is an important determinant affecting either drug response or susceptibility
to adverse drug reactions. Several studies have highlighted the importance of ethnicity in
influencing drug response variability that should be considered during drug development.
Our objective is to characterize the genetic variability of some pharmacogenes involved in
the response to drugs used for the treatment of Metabolic Syndrome (MetS) in Tunisia and
to compare our results to the worldwide populations. A set of 135 Tunisians was genotyped
using the Affymetrix Chip 6.0 genotyping array. Variants located in 24 Very Important Phar-
macogenes (VIP) involved in MetS drug response were extracted from the genotyping data.
Analysis of variant distribution in Tunisian population compared to 20 worldwide populations
publicly available was performed using R software packages. Common variants between
Tunisians and the 20 investigated populations were extracted from genotyping data. Multidi-
mensional screening showed that Tunisian population is clustered with North African and
European populations. The greatest divergence was observed with the African and Asian
population. In addition, we performed Inter-ethnic comparison based on the genotype fre-
quencies of five VIP biomarkers. The genotype frequencies of the biomarkers rs3846662,
rs1045642, rs7294 and rs12255372 located respectively in HMGCR, ABCB1, VKORC1 and
TCF7L2 are similar between Tunisian, Tuscan (TSI) and European (CEU). The genotype
frequency of the variant rs776746 located in CYP3A5 gene is similar between Tunisian and
African populations and different from CEU and TSI. The present study shows that the
genetic make up of the Tunisian population is relatively complex in regard to pharmaco-
genes and reflects previous historical events. It is important to consider this ethnic difference
in drug prescription in order to optimize drug response to avoid serious adverse drug
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reactions. Taking into account similarities with other neighboring populations, our study has
an impact not only on the Tunisian population but also on North African population which are
underrepresented in pharmacogenomic studies.
Introduction
Drug response varies between individuals owing to disease heterogeneity, genetic and environ-
mental factors [1–3]. It depends on absorption and distribution of drug to the targeted recep-
tors and enzymes that further metabolize it and ultimately excrete it from the body [4]. During
this process, genetic variation may alter the therapeutic response of an individual [5–7].
Indeed, ethnic diversity plays a major role in drug response variability, which may have an
important regulatory aspect that should be also considered during drug development [8]. Con-
sequently, treatment and recommended doses should not be extrapolated from one ethnic
group to another [9]. Pharmacogenetic studies explore the genetic impact of the inter-individ-
ual variability of drug response, involving both the pharmacokinetics and pharmacodynamics
[3]. The clinical implementation of pharmacogenetics in therapeutic approaches, aims to opti-
mize specific drug regimens and drug dosage. This, may have a great advantage in, improving
clinical outcomes and avoiding major clinical complication such as congestive heart failure,
hepatic and renal disorders [10, 11].
During the last years, the incorporation of pharmacogenetic testing in clinical trials has
gained interest. This has been facilitated with the advancement in microarray based methods
that allows genotyping Single Nucleotide Polymorphisms (SNPs) in many samples simulta-
neously. This method leads to the identification of loci responsible for drug response variabil-
ity and adverse reactions [12, 13]. Despite the double burden of communicable and non
communicable diseases (NCDs) on the health system, some populations like African still
remain poorly studied at the pharmacogenetic level. The Metabolic Syndrome (MetS) is one of
the diseases which prevalence is increasing dramatically in North Africa. In Tunisia, it affects
up to 30% of the population in urban region [14]. MetS is defined by a cluster of multiple met-
abolic abnormalities, including central obesity, hypertension, dyslipidemia and insulin resis-
tance that directly increase the risk of coronary heart disease (CHD), other forms of
cardiovascular atherosclerotic diseases (CAD), Type 2 Diabetes Mellitus (T2DM), and prema-
ture death [13, 15]. Until now, there is no effective drug treatment prescribed to manage all
components of MetS. Indeed each syndrome component is treated individually, so miscella-
neous types of drugs are used in the treatment of this syndrome, including weight losing
drugs, antilipemic, antihypertensives and antidiabetics [15]. This strategy is not always reliable;
indeed the individuals do not respond equally to the same treatment. Such differences may
be due to diverse mean values of quantitative traits or different genotypic frequency distribu-
tions of the variants between populations [16]. For instance, many studies have reported the
involvement of variants annotated as Very Important Pharmacogene (VIP) variants in the out-
come of anticoagulant, oral anti-diabetic [17, 18] and statins [19]. A significant proportion of
ethnic variability in the response to coumarin anticoagulant (AVK), prescribed to treat and
prevent arterial and venous thromboembolic disorders in MetS, has been attributed to the
differential frequencies of variant in CYP2C9 and VKORC1 genes[20, 21]. The diversity of dis-
tribution of functional variants, rs9923231 located in VKORC1, rs1799853 and rs1057910
located in CYP2C9, and which are known to influence AVK dose requirement, has been
highlighted [21]. These common polymorphisms were shown to confer a high risk towards
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over-anticoagulation, predisposing the individuals carrying these polymorphisms to hemor-
rhagic incidents [22]. In addition, a variable response to beta-blockers used in the treatment of
hypertension, including propranolol [23], metoprolol, atenolol [24] and clopidogrel [25, 26]
was observed in patients of European and African origins which can trigger a stroke [27, 28].
Other serious adverse outcomes of drugs in MetS are reported such as sudden death, bleeding
events, myopathy, [2, 20, 27, 29]. All these ADR engender high social and financial burden.
Considering the burden of public health, and genetic variability in response to treatment, we
have chosen in the present study to characterize the genetic variability of some pharmacogenes
involved in the response to drugs used for the treatment of MetS in Tunisia and to compare
our results to the worldwide human populations.
Materiel & methods
Study participants and genotyping
A set of 135 Tunisian healthy individuals including; 32 women and 103 men, originating from
two regions (the Capital Tunis and the coastal city of Monastir) were genotyped in a previous
study [30] using the AffymetrixChip 6.0 genotyping array. Genotyping data were generated
after the variants calling performed with R CRLMM package [31]. The study was approved by
the Ethics Committee of the Institut Pasteur (Tunis, Tunisia-Registration numbers
IRB00005445, FWA00010074, and PV09/06, IRB# 0000000044). All participants provided
written informed consent.
Selection of very important pharmacogenes and variant
We selected a set of very important pharmacogenes (VIP) involved in MetS components drug
response from the PharmGKB database (http://www.pharmgkb.org) which provides an over-
view of significant genes involved in the metabolism or response to one or several drugs. VIP
genes were chosen through extensive review of a variety of sources, including the U.S. Food
and Drug Administration (FDA) biomarker list, FDA-approved drug labels with pharmacoge-
netic information, and Clinical Pharmacogenetic Implementation Consortium (CPIC) nomi-
nations [32]. Additionally, we considered a gene as a VIP if it is associated with a large number
of variant annotations and having high-level of clinical annotations. Furthermore, genetic vari-
ants were chosen from published polymorphisms associated with VIP through an extensive
bibliographic search.
Genotyping data
PLINK v2 [33] was used to extract variants of the selected VIP. The genotypic data of individu-
als from 22 other populations were downloaded from the International HapMap Project phase
III (ftp://ftp.ncbi.nlm.nih.gov/hapmap/) and published data [34, 35]. The studied populations
included those of (1) African ancestry in the South Western USA (ASW); (2) Northwestern
and western European ancestry populations of Utah from the CEPH collection (CEU); (3)
Han Chinese in Beijing, China (CHB); (4) Chinese population of metropolitan Denver, Colo-
rado, USA (CHD); (5) Gujarati Indians in Houston, Texas, USA (GIH); (6)Luhya people in
Webuye, Kenya (LWK); (7) people of Mexican ancestry living in Los Angeles, California, USA
(MEX); (8) Maasai people in Kinyawa, Kenya (MKK); (9) Toscani people of Italy (TSI); and
(10)Yoruba in Ibadan, Nigeria (YRI).
Genotypic data from other population mainly from South Europe and North Africa (Alge-
ria (ALG), Egypt (EGY), Libya (LIB), Tunisia Douiret (TN_Ber), Lebanon (LEB), South
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Morocco (MCS), North Morocco (MCN), Sub-Saharan (SAH), South Spain (SPS), North
Spain (SPN) Spain Basc (SBA) were download from the previous published study [16, 35].
Quality control analysis
Genotypic data were managed using the PLINK v2 software. Variants were excluded if they
are deviating from the Hardy-Weinberg equilibrium (HWE) (p-value< 10−4), minor allele fre-
quency (MAF) < 10−2 and have missed genotyping rate to 95% for each of the studied
populations.
Statistical analysis
To infer cryptic population structure from genomic data, principal component analysis (PCA)
based on pruned genotypic data was performed using SNPrelate R package [36]. Cryptic popu-
lation structure defines a population structure that is difficult to detect using visible characters
but may be significant in genetic terms[37, 38]. Indeed, the information about the population
origin is given by the study participants. This information is subjectively based on geographic
location, physical and cultural characters. The genotypic data and estimated allele frequencies
might be used to determine if a given assignment of individuals to a population, based on sub-
jective criteria, mirrors a natural assignment in genetic terms (admixture and gene flow).
Genetic data can be useful to determine the cryptic relatedness among populations and to
shape the false matches due to the probabilistical assignment of population. In addition, we
used PLINK v2, and “rgl” R package [39], to generate multidimensional scaling plot (MDS)
and three dimensional MDS (3D MDS) from the same data.
The genotype frequencies of the selected VIP in Tunisian population, were calculated and
compared with 10 HapMap populations, using SNPassoc R package [40]. In this step of analy-
sis, we have considered only the HapMap project populations due to the complete genotypic
data. The inter-ethnic genotypic frequency comparison was performed using the Chi-square
test and Bonferroni’s adjustement was applied to the level of significance set at a p-value
threshold of 5% devided by the number of studied loci.
Analyses of population genetic structures
Fixation Index (Fst) and Structure are two common analyses in population genetic studies.
The R package Hierfstat [41] was used in order to assess the degree of similarity in genetic
structure between the different ethnic populations, we calculated pairwise Fst values and evalu-
ate the magnitude of differentiation among geographic populations (0 indicating no diver-
gence, 1 meaning complete separation). Pairwise Fst values between the Tunisian population
and the other 10 HapMap populations were calculated. To further investigate variation at the
VIP variants in terms of population structure, we used the STRUCTURE ver. 2.3.4 software
[38, 42] which is based on the bayesian clustering algorithm to assign the samples within a
hypothetical K number of ancestries. We set a range of possible number of clusters ranging
from K = 2 to K = 10 and 24 trials were run for each K. The Markov Chain Monte Carlo itera-
tion for each structure analysis was run for 10000 after an initial burn-in period of 10000 steps.
In order to assess the most likely number of clusters, we calculated delta K as proposed by
Evanno et al. [43]. The similarity of the runs at each K level was evaluated by the CLUMPP
software as implemented at the online [44]. The Distruct software was used to visualize the
best alignment of subpopulation inferring population substructure and individual assignment
across the best runs at each k level [45].
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Results
Based on a large bibliographic search and PhamaGKB interrogation, we selected 24 pharmaco-
genes implicated in MetS components drug response modulation listed in Table 1 including
class of drug, drug name, gene name, description and category family of genes, pharmacoki-
netic phase of drug metabolism, chromosomal localization and the corresponding VIP variant.
The studied genes belong to ABC transporters family, cytochrome P450 family and G-coupled
receptor family (Table 1). A total of 1056 variant on 24 pharmacogenes were identified in the
Tunisian population and kept after quality control steps for subsequent analysis.
For inter-ethnic genotypic frequency comparison and population structure analyses pur-
poses, we kept 743 shared variants among the 22 worldwide studied populations. The MDS
analysis describing the genetic landscape of these pharmacogenes shows a cluster of the Tuni-
sian population with the North African populations (Algeria, Morocco, Egypt . . .), Tuscan and
CEU were distinguished from the Asian and Sub Saharan African populations (Fig 1). This
result was further confirmed using PCA analyses (S1 Fig). A great divergence was observed
between the Asian populations and LWK (S1 Fig).
Among the 743 variants shared between the studied populations, five clinically relevant VIP
variants were identified. Therefore, we performed an inter-ethnic comparison based on their
genotypic frequencies. We found that the genotype frequencies of the following variants
involved in the anticoagulant sensitivity; rs3846662 (HMGGR), rs1045642 (ABCB1), rs7294
(VKORC1) and rs12255372 (TCF7L2), were similar between the Tunisian population, Tuscany
and the European populations (CEU); (p>>0.05/510). The genotypic frequencies of the
rs776746 variant located in the CYP3A5 gene involved in the hypolipidemic susceptibility are
similar between Tunisian and African populations (MKK, LWK, YRI) and significantly differ-
ent from European (CEU) and Asian (CHD, CHB); (p<<0.05/510) (Table 2).
In order to assess the degree of similarity in the genetic structure between the different eth-
nic populations, we calculated the pairwise Fst values among the Tunisian population and the
other 10 HapMap populations ranged from 0.00802 to 0.41201 (Table 3). Comparing Tunisia
to other populations, the lowest level of differentiation was observed between the inner and
costal part of centeral Tunisia (Fst = 0.01182), followed by the TSI (Fst = 0.02872) and MEX
(Fst = 0,0269) populations, whereas the greatest divergence was observed with the LWK popu-
lation (Fst = 0,35929).
Bayesian-based STRUCTURE analysis (Fig 2) provided complementary methods for visual-
izing patterns of genetic similarity and differentiation between the Tunisian population and
the other 22 populations. According to the Evanno’s ΔK method for STRUCTURE, K = 3 was
selected to detect the most likely number of genetic clusters (S2 and S3 Figs). The barplot
shows three components: African, Asiatic and European. For the North African populations
cluster regrouping (TN_MC, TN_TC, ALG, EGY, MCN, MCS, SAH and LIB), the European;
(CEU, TSI, MEX, SPB, SPN, SPS), East African (MKK, LWK, ASW) and Asiatic subgroups
(CHD, CHB). This graph demonstrates the predominance of the African and European com-
ponents. Thus, reflecting that the Tunisian population is a mosaic of different populations
which reflects the existence of different gene flows that have influenced genetic variability of
the response to treatments.
Discussion
In the recent years, the use of pharmacogenomics witnessed important success in the improve-
ment of healthcare by developing therapeutic treatment and predicting individual response
[23]. Distribution of VIP variants exerts irreplaceable significance in pharmacogenomics
knowledge [25]. In the present study, we showed that some VIP variants involved in MetS
Pharmacogenetic landscape of Metabolic Syndrome drug response in Tunisia and worldwide populations
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Table 1. Basic information of selected pharmacogenes.
Class of Drug Drug name Genes ID Description Category Family Phase Chr Localisation of Gene VIP (High
evidence level)
Anticagulant Clopidogrel
(Palvix)
ABCB1 ATP binding cassette
subfamily B member 1
ABC transporters
superfamily
Other 7 chr7:87,133,179–
87,342,638
rs10545642
rs1128503
rs2032582
CYP2D6 cytochrome P450 family 2
subfamily D member 6
Cytochrome P450
superfamily
phaseI 22 chr22:42126499–
42130881
rs3892097
CYP2C19 cytochrome P450 family 2
subfamily C member 19
Cytochrome P450
superfamily
phaseI 10 chr10:96,522,438–
96,612,962
rs1057910
rs4244285
P2RY12 purinergic receptor P2Y,
G-protein coupled, 12
G-protein coupled receptor Other 3 chr3:151,054,631–
151,102,600
Acenocoumarol CYP2C9 cytochrome P450 family 2
subfamily C member 2
Cytochrome P450
superfamily
phaseI 10 chr10:96,698,415–
96,749,148
rs1057910
VKORC1 vitamin K epoxide
reductase complex, subunit
1
Vitamin K epoxide
reductase
phaseI 16 chr16:31,102,163–
31,106,320
rs9934438 rs7294
Antidiabetic Biguanide/
Metformine
SLC22A1 solute carrier family 22
(organic cation
transporter), member 1
Organic cation transporte other 6 chr6:160,542,863–
160,579,750
Biguanide/
Metformine
SLC22A2 solute carrier family 22
(organic cation
transporter), member 2
Organic cation transporte other 6 chr6:160,637,794–
160,679,963
Biguanide/
Metformine
SLC47A1 solute carrier family 47
(multidrug and toxin
extrusion), member 1
Multidrug and toxin
extrusion
other 17 chr17:19,437,167–
19,482,346
Biguanide/
Metformine
SLC47A2 solute carrier family 47
(multidrug and toxin
extrusion), member 2
Multidrug and toxin
extrusion
other chr17:19,581,628–
19,620,043
Biguanide/
Metformine
ATM ATM serine/threonine
kinase
Phosphatidylinositol
3-kinase-related kinase
superfamily
Other 11 chr11:108,093,559–
108,239,826
rs11212617
TZD/
Pioglitazone
PPARG peroxisome proliferator-
activated receptor gamma
Nuclear receptors
superfamily
Other 3
TZD/
Rosiglitazone
PGC-
1alpha
peroxisome proliferative
activated receptor, gamma,
coactivator 1 alpha
Nuclear receptors
superfamily
Other 5 chr5:51,454,249–
51,553,921
rs1801282
TZD/
Troglitazone
RETN Resitin 19 chr19:7,669,086–
7,670,454
Leptin
LEPR
leptin receptor Cytokine receptors
superfamily
Other 1 chr1:65,420,652–
65,635,428
TNFalpha Tumor Necrosis Factor Tumor necrosis factor
receptor
31 chr6:31,543,344–
31,546,112
Sulphonylurea KCNJ11 potassium channel,
inwardly rectifying
subfamily J, member 11
Potassium channel Modifier 11 chr11:17,406,796–
17,410,206
rs5215 rs5219
rs757110
ABCC8 ATP binding cassette
subfamily C member 8
ATP-binding cassette
(ABC) transporters
Modifier 11 chr11:17,414,432–
17,498,392
KCNQ1 potassium channel, voltage
gated KQT-like subfamily
Q, member 1
Potassium Channel
superfamily
Other 11 chr11:2,466,221–
2,870,340
TCF7L2 transcription factor 7-like 2
(T-cell specific, HMG-box)
DNA-binding proteins. Other 10 chr10:114,710,009–
114,927,436
rs12255372
(Continued)
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drug response, exhibited a great genetic variation among the studied populations, which
directly impacts on the delivery of individualized medicine. The ethnicity should be taken into
consideration, in routine clinical practice to ensure the efficacy and safety of the drug at the
population level [46][47]. Our data confirm that ethnicity, even among close populations plays
a significant role in differential distribution of variants implicated in drug response or ADR
[46]. In Tunisian population, these variants displayed a close genetic affinity with the North
African (ALG, LIB, MCN, MCS), Middle Eastern (EGY, LEB) and European populations (TSI,
CEU, SPS, SBA, SPN) but they were distinct from the South Africans and Asians. Our results
are in agreement with those of the study of Mizzi C et al, 2016, that used tailored DMET array
and compared the generated data of 11 European populations against Saudi Arabian, Asian
and South African populations. The study showed that there are no significant differences
among the European populations. The great divergence was observed among European, Asian
and South African population [46]. Another study of Abdelhedi et al., focused on the CYP2C9
and CYP2C19 variants implicated in the metabolism of anticoagulant response, concluded that
Tunisians were similar to Europeans and Middle Easterners with regard to the allelic frequen-
cies [27]. Pairwise Fst values of clinically relevant VIP variants, in our study, also revealed a
more similarity between Tunisian, Tuscan and European populations (CEU). This was con-
firmed with analysis using admixture that showed the heterogeneity of Tunisian population
and the contribution of the European, North African components. These observations were
also reported on mitochondrial DNA, Y chromosomal and autosomal markers and interpreted
as influences from different migration events [34, 48–50]. Obviously, differences in admixture
history exert an important impact in the allelic and genotypic distribution of variants at the
population level [47]. In the present study, five polymorphisms characterized as clinically
Table 1. (Continued)
Class of Drug Drug name Genes ID Description Category Family Phase Chr Localisation of Gene VIP (High
evidence level)
Lipid lowring
Fenofibrate
Flavastatin CYP2C9 Cytochrome P450 family 2
subfamily C member 9
Cytochrome P450 phaseI 10 chr10:96,698,415–
96,749,148
Lovastatin ABCB1 ATP binding cassette
subfamily B member 1
ABC transporters
superfamily
Other 7 chr7:87,133,179–
87,342,638
rs1128503
Atorvastatin ABCB1 ATP binding cassette
subfamily B member 1
ABC transporters
superfamily
Other 7 chr7:87,133,179–
87,342,638
rs2032582,
ABCA1 ATP-binding cassette, sub-
family A (ABC1), member
1
ABC transporters sub-
family A
Other 9 chr9:104,781,003–
104,928,246
rs12003906
CYP2C9 Cytochrome P450 family 2
subfamily C member 9
Cytochrome P450 phaseI 10 chr10:96,698,415–
96,749,148
rs1057910
PPARA Peroxisome proliferator-
activated receptor alpha
Nuclear hormone receptor
superfamily
22 chr22:46,546,499–
46,639,653
SCLO1B1 Solute carrier organic
anion transporter family,
member 1B1
Solute carrier family Others chr22:46,546,499–
46,639,653
rs4149056
rs4149081
rs4363657
rs4149015
HMGCR 3-hydroxy-
3-methylglutaryl-CoA
reductase
HMGCR superfamily 5 chr5:74,632,993–
74,657,926
rs17238540
rs3846662
rs17244841
CYP3A5 cytochrome P450 family 3
subfamily A member 5
Cytochrome P450
superfamily
Phase I 7 chr7:99,245,812–
99,277,649
rs776746
The list of 24 pharmacogenes implicated in MetS components drug response modulation, including class of drug, drug name, gene name, description and category
family of genes, pharmacokinetic phase of drug metabolism, chromosomal localization and the corresponding common VIP variant.
https://doi.org/10.1371/journal.pone.0194842.t001
Pharmacogenetic landscape of Metabolic Syndrome drug response in Tunisia and worldwide populations
PLOS ONE | https://doi.org/10.1371/journal.pone.0194842 April 13, 2018 7 / 16
Fig 1. Multidimensional scaling plot analysis of the Tunisian subpopulation and worldwide populations. The plot reveals three distinct clusters
showing that the Tunisian population present a close affinity with the North Africans and Europeans and distinct from South Africans and Asians.
Tunisian population; Capital Tunis TU_TC, coastal city of Monastir TU_MC (AffymetrixChip 6.0 genotyping array), African ancestry in the south
Western USA (ASW); a northwestern European population (CEU); the Han Chinese in Beijing, China (CHB); a Chinese population of metropolitan
Denver, Colorado, USA (CHD); the Gujarati Indians in Houston, Texas, USA (GIH); the Japanese population in Tokyo, Japan (JPT); the Luhya people
in Webuye, Kenya (LWK); people of Mexican ancestry living in Los Angeles, California, USA (MEX); the Maasai people in Kinyawa, Kenya (MKK); the
Tuscan people of Italy (TSI); and the Yoruba in Ibadan, Nigeria (YRI); data from HapMap were retrived in March 2016. It is available by FTP: ftp://ftp.
ncbi.nlm.nih.gov/hapmap/ and Algeria (ALG), Egyptia (EGY), Libya (LIB), Tunisia Dwiret TUN_Ber, Lebanon (LIB), Morocco South (MCS), Morocco
North (MCN), Spain South (SPS), Spain North (SPN), Spain Basc (SBA),: Sub-Saharan (SAH), Canary Island (CIS); data from the literature [34, 35].
https://doi.org/10.1371/journal.pone.0194842.g001
Table 2. Genotype frequency of significant VIP variants in Tunisian population (n = 135) compared with ten HapMap populations.
Gene name SNP ID Freq.(TUN) p-values against ten populations after Bonferroni correction
AA AB BB CEU TSI ASW LWK MKK YRI CHB CHD GIH MEX
CYP3A5 rs776746 0;66 0;26 0;08 1.403e-05 0.0001 0.0056 0.1242 0.0952 0.1507 0.04827 0.1836 0.2151 0.2151
HMGCR rs3846662 0.29 0.47 0.25 0.4508 0.8194 7.205e-12 2.2e-16 8.61e-10 2.2e-16 0.9271 0.8383 0.0226 0.2502
ABCB1 rs1045642 0.49 0.33 0.18 0.0262 0.0152 0.0007 - 0.0004 6.802e-06 0.4246 0.0066 0.0066 0.0002
VKORC1 rs7294 0.65 0.27 0.09 0.0902 0.0014 0.0013 4.081e-07 3.722e-06 2.226e-06 6.742e-05 0.0005 0.0001 0.0013
TCF7L2 rs12255372 0.48 0.33 0.19 0.0487 0.0264 0.0071 0.0071 0.0236 - 0.02361 4.248e-10 0.0002 0.0216
Bonferroni correction was applied to the level of significance, which was set at (p.value < 0.05/510 = 0.001);p.value > (0.05/510) assigned in bold represent differences
not statistically significant between Tunisia and the compared population, 0.00 not observed genotypes; -: not successfully genotyped or not compared by chi-square
test. TUN = (TN_Mc/TN_TC), MEX = Mexican ancestry in Los Angeles, California; TSI = Toscans in Italy; LWK = Luhya in Webuye, Kenya; ASW = African ancestry
in Southwest USA; GIH = Gujarati Indians in Houston, Texas; MKK = Maasai.
https://doi.org/10.1371/journal.pone.0194842.t002
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relevant VIP variant, were selected, based on previous pharmacogenomics research to be fur-
ther investigated (S4 Fig).
The variant rs7294; 3730 G>A transition located on chromosome 16 in the 3’Untranslated
Region (UTR) of VKORC1 gene. This gene encodes the vitamin K epoxide reductase protein,
which is a crucial enzyme in vitamin K cycle and therefore involved in inter-individual drug
variability of the majority of coumarin derivatives, such as warfarin, acenocoumarol and phen-
procoumon which are frequently prescribed as oral anticoagulants to treat and prevent throm-
boembolism [51]. Because there is a large inter-individual and intra-individual variability in
dose-response and a narrow therapeutic window, treatment with coumarin derivatives is chal-
lenging. Some polymorphisms in VKORC1 were associated with lower dose requirements and
a higher risk of bleeding [52]. Patient with the TT genotype may require an increased dose to
attend the curative effect of the anti-coagulant such as phenprocoumon or acenocoumarol as
compared to patients with the TC or CC genotypes[53]. The frequency of TT genotype of
rs7294 was generally lower in Tunisian population (0.09) than in African populations (MKK,
LWK, ASW, YRI) respectively equal to (0.18, 0.28, 0.23) and East Asian populations (CHB,
CHD) (0.89, 0.86) and similar to Europeans (CEU, MEX, TSI) (0.13, 0.09, 0.08) and Central
Table 3. Estimating of pairwise Fst among the 11 populations.
TN_TC TN_MC ASW CEU CHB CHD GIH LWK MEX MKK TSI YRI
TN_TC 0
TN_MC 0.01182 0
ASW 0.15553 0.23478 0
CEU 0.06517 0.04978 0.29914 0
CHB 0.02268 0.02350 0.21765 0.09797 0
CHD 0.06546 0.09602 0.26864 0.11989 0.00179 0
GIH 0.10636 0.14372 0.17866 0.08929 0.18313 0.21073 0
LWK 0.24521 0.32005 0.02744 0.35559 0.27347 0.32958 0.22448 0
MEX 0.02691 0.02635 0.2041 0.031436 0.04645 0.06478 0.08524 0.27337 0
MKK 0.12447 0.21536 0.03173 0.25203 0.18501 0.18924 0.15348 0.09203 0.16398 0
TSI 0.02872 0.01614 0.26226 0.00802 0.06736 0.11424 0.09639 0.34295 0.02816 0.22575 0
YRI 0.27506 0.35929 0.01749 0.41201 0.32575 0.37106 0.29278 0.00276 0.32288 0.08404 0.38693 0
The pairwise differences Fst values between 11 populations. Fst value is less than 0.15 represent that there is no genetic differentiation between the two populations. The
lowest level of differentiations were found between TN_TC and TN_MC (Fst = 0,01182) followed by the TSI (Fst = 0.02872) and MEX (Fst = 0,0269) populations,
whereas the greatest divergence was observed with the LWK population (Fst = 0,35929).
https://doi.org/10.1371/journal.pone.0194842.t003
Fig 2. STRUCTURE analysis of the genetic relationship between 24 populations. K is the possible numbers of
parental population clusters. One color represents one parental population into different color segments. Best K level
was observed at K = 3, where a vertical the proportion of each ancestral component in a single individual is represented
by a vertical bar divided into 3 colors. 601 markers study—displaying results for runs with highest likelihood out of 27
runs in each cluster K3 to 10. Black vertical lines identify the population boundaries. The height extent of each color
within an individual’s color bar corresponds to the estimated membership of the individual in one of the clusters; each
cluster is assigned a separate color. The bars with multiple colors can be interpreted as genetic admixture or as relative
probabilities of belonging to the different clusters.
https://doi.org/10.1371/journal.pone.0194842.g002
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Asians (GIH) (0.03) (S1 Table). Indeed, this result suggests that the Tunisians might require a
lower dose of acenocoumarol or phenprocoumcon to achieve the therapeutic effect. Thus, the
dosage regimen may be optimized on the specific genotypic frequency in Tunisian population.
The rs1045642 (A>G) transition is synonymous variant located on ABCB1 (MDR1) gene
which is one of many ubiquitous adenosine triphosphate (ATP)-binding cassette (ABC) genes
that is responsible for cellular homeostasis [54, 55]. The ABCB1C3435T (rs1045642) is exten-
sively studied and some research showed that the ABCB1C3435T genotype influences the
absorption of clopidogrel [56] and is associated with poor clopidogrel response. Conversely,
the frequencies of AA and AG genotypes of rs1045642 which respectively equal to (0.49, 0.33),
in Tunisian population, were respectively much lower than that are reported in other popula-
tions. (S1 Table). In this case, AA and AG genotypes may have an increased risk of major
adverse cardiovascular events such as cardiovascular death, myocardial infarction, or stroke,
when treated with clopidogrel in people with acute coronary syndrome or myocardial infarc-
tion as compared to people with GG genotypes.
The rs3846662 located on intron 13 of HMGCR, was associated with differential induction,
upon simvastatin exposure, of expression of full-length HMGCR transcript versus alternatively
spliced transcript lacking exon 13 (HMGCRv_1). Homozygous individuals A/A exhibit 40%
greater induction of full-length transcripts and 20% less alternatively spliced HMGCRv_1 tran-
script relative to A/G or G/G subjects [57]. These differences may have implications for simva-
statin efficacy, since the AA genotype of rs3846662 was associated with the increased induction
of the alternatively spliced transcript is correlated with reduced response to simvastatin [57].
For this variant, the Tunisian and European populations were genetically different to the Afri-
can population (MKK, LWK, YRI) which represented a highly frequencies of the defective AA
genotype which consisted respectively to the values of (0.93, 0.71, 0.92). These results mirror
that the African populations were more sensitive to the statin treatment than Tunisian popula-
tion which seems having a response similar to the European (TSI, CEU) (0.35, 0.32) (S1
Table).
Rs776746 (C/T) variant located on CYP3A5 gene which is implicated in the biotransforma-
tion of the statin drugs, this variant creates a splice site in intron 3, resulting in altered mRNA
splicing. The alternatively spliced isoform has an insertion in intron 3, which changes the read-
ing frame and results in a premature termination codon and hences a non-functional protein
[58]. Individuals with rs776746 TT genotype are considered to be CYP3A5 poor metabolizes.
Indeed, Subjects carrying this genotype have a poor response to lipid lowering drugs such as
statin (atorvastatin, simvastatin, lovastatin) [59], consequently they may develop severe muscle
damage linked to this inappropriate treatment[60]. The aforementioned variant is the most
frequent and well-studied variant allele of CYP3A5. Its frequency varies widely across human
populations [61, 62]. In Tunisian population, it was more similar to the Africans (p.
value < 0.05/510) and differed significantly to the European and Asian population (p.
value > 0.05/510). The frequency of rs776746 TT in Tunisian and African were low, it ranged
between (0.01 to 0.08). Thus, these populations may have similar statin metabolism and will be
of great clinical significance in determining future therapeutic approaches. Regarding the vari-
ant rs776746, our findings show that Tunisian population has significant similarities with Afri-
can populations in predicted atorvastatin response. Yet, they display a distinct profile on PCA.
This result could be due to the high heterogeneity of the Tunisian genetic structure composed
of European, African, and Asian (Near Eastern) components. For this reason, it seems plausi-
ble that for some VIP variant, Tunisians are similar to the Europeans and for others, Tunisians
are similar to the Africans. As stated in the study of Mizzi C et al,. 2016, the population groups
are distinguished according to the results of PCA or admixture analysis using genotyping data.
This approach cannot lead to broad generalizations in the application for VIP variants at the
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individual level. Although, the approaches aiming to identify clinically relevant actionable VIP
variants are conducted in small number of variants. Moreover, this result is in agreement with
other studies showing that there are multiple pharmacogenomic profiles across African and
non African populations which could affect the safety and efficacy of many therapeutic drugs
with CYP3A5 substrate [59, 61]. In addition a considerable heterogeneity in North Africa but
not in other geographic regions, has been highlighted revealing a selective pressure on
CYP3A5 gene [63]. Based on the rich historic background of Tunisia, we suggest that adaptive
T allele of rs776746 might have been introduced by a relatively recent gene flow.
The intronic variant rs12255372, transition 113049143 G>T located on chromosome 10 of
TCF7L2 gene have been thoroughly studied and found to be associated with increased risk of
T2DM [64, 65]. The mechanisms by which TCF7L2 affects susceptibility to the disease remain
unraveled. Nevertheless, several studies have shown that decreased TCF7L2 protein expression
inhibits the insulin secretory response to an oral glucose through impaired incretin action[66].
The GODART study performed on Scottish subjects receiving sulfonylurea, showed an associ-
ation of rs12255372 risk allele with reduced effect of Sulfonylureas hypoglycemic response [65,
66]. The results revealed that the TT patients undergoing early sulfonylurea treatment had
approximately two-fold higher probability to fail the sulfonylureas medication (57% versus
17% for TT versus GG respectively)[65]. Conversely, our study shows that the frequency of
Tunisians carriers of rs12255372 TT genotype (0.19) is much lower than TSI, ASW, LWK,
MKK and CHB (respectively equal to 0.23, 0.22, 0.22, 0.29, 0.29) and much higher than CEU
and MEX (0.07, 0.09). Tunisian population seems to be good responder to Sulfonylureas
which should be the first line drug for patients, replacing insulin injections. Genotyping the
rs12255372 located in TCF7L2 should be considered when using Sulfonylureas treatment [67].
SNP array designed for the Genome Wide Association Study (GWAS) exploited in our
study do not allow to fully assess the contributions of variants implicated in MetS drugs
response due to the non-uniform coverage of all the chromosomal regions. Indeed, specialised
pharmacovariants chip like DMET array increases the power to identify common and rare var-
iations validated for their involvement in drugs metabolism [68–70].
The current clinical pharmacogenomics practice considered that inter-individual drug
response variability is mainly based on genetic common variants [1, 3, 46, 47, 71]. For this rea-
son, in our study, we have focused on common variants among Tunisian compared to other
populations. Nevertheless, it is well known that rare variants are expected to have more effects
on response to drug than common variants because they will not have been subject to purify-
ing selection after the recent expansion of the human population. [72, 73].
Conclusion
The present study showed that Tunisian population is genetically heterogeneous regarding the
studied pharmacogenes involved in the response to the MetS components. The allelic and
genotypic frequencies do not differ homogenously among the components. This shows the
complexity of the genetic components of response to treatment in admixed populations. This
study should be extended to other North African population to take into account their pecu-
liarities in order to effectively orient dose and drug prescription to ovoid serious adverse
reactions.
Supporting information
S1 Fig. Principal component analysis of the Tunisian subpopulation and worldwide popu-
lations. The plot reveals three distinct clusters showing that the Tunisian population present a
close affinity with the North Africans and Europeans and distinct from South Africans and
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Asians. Tunisian population; Capital Tunis TU_TC, coastal city of Monastir TU_MC (Affyme-
trixChip 6.0 genotyping array), African ancestry in the south Western USA (ASW); a north-
western European population (CEU); the Han Chinese in Beijing, China (CHB); a Chinese
population of metropolitan Denver, Colorado, USA (CHD); the Gujarati Indians in Houston,
Texas, USA (GIH); the Japanese population in Tokyo, Japan (JPT); the Luhya people in
Webuye, Kenya (LWK); people of Mexican ancestry living in Los Angeles, California, USA
(MEX); the Maasai people in Kinyawa, Kenya (MKK); the Tuscan people of Italy (TSI); and
the Yoruba in Ibadan, Nigeria (YRI); data from HapMap: ftp://ftp.ncbi.nlm.nih.gov/hapmap/
and Algeria (ALG), Egyptia (EGY), Libya (LIB), Tunisia Dwiret TUN_Ber, Lebanon (LIB),
Morocco South (MCS), Morocco North (MCN), Spain South (SPS), Spain North (SPN), Spain
Basc (SBA),: Sub-Saharan (SAH), Canary Island (CIS); data from the literature.
(TIFF)
S2 Fig. Distruct barplot result. The figure shows the different bar plots according to the dif-
ferent K number.
(DOCX)
S3 Fig. Best_K_By_Evanno-Delta K By K graph. The graph shows the best K equal to 3
according to delta K as proposed by Evanno.
(TIF)
S4 Fig. Analysis pipeline.
(TIF)
S1 Table. Genotype frequencies of clinical relevant VIP variant in Tunisia an ten HapMap
populations. The table reveals the similarities or divergences of the Tunisian population to the
other studied populations. This table highlight that the genotype frequencies of VIP variants
significantly affect a population’s response to a given drug.
(XLSX)
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